Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Peter H. Griffith net worth and biography

Peter Griffith Biography and Net Worth

Exec. VP & CFO of Amgen

Peter Griffith became executive vice president and Chief Financial Officer in January 2020. Previously, he was executive vice president, Finance.

He joined Amgen in 2019 from Sherwood Canyon Group, LLC, a private equity and advisory firm, where he served as president. Previously, he retired from EY (formerly Ernst & Young), a leader in assurance, tax, transaction and advisory services, after a distinguished career there, including almost 22 years as a partner. Most recently, Griffith served as EY’s Global Vice Chair, Corporate Development with responsibility for driving the firm’s international growth and expanding its capabilities worldwide. He also served as EY’s Global Managing Partner, Operations and Finance during a time when the organization grew annual revenues more than 25 percent to over $27 billion. This latter role included the Finance and Accounting, Corporate Development, Tax, and Treasury functions. Prior to EY, he was a Managing Director and head of the investment banking division of Wedbush Securities Inc.

Griffith was recognized by the Los Angeles chapter of the National Association of Women Business Owners as its first ever “Man of the Year.” He is a member of the Advisory Board for USC’s Shaffer Center for Health Policy and Economics. He is also a member of the USC Marshall School of Business Board of Leaders.

He received his bachelor’s degree from the University of Southern California’s Marshall School of Business.

How old is Peter H. Griffith?: Mr. Griffith is currently 65 years old. There are 7 older executives and no younger executives at Amgen. Learn More on Peter H. Griffith's age.
How do I contact Peter H. Griffith?: The corporate mailing address for Mr. Griffith and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Peter H. Griffith's contact information.
Has Peter H. Griffith been buying or selling shares of Amgen?: Peter H. Griffith has not been actively trading shares of Amgen within the last three months. Learn More on Peter H. Griffith's trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 4,213 shares worth more than $1,235,082.41. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 5/3/2024.

Peter H. Griffith Insider Trading History at Amgen

Peter H. Griffith Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $287.87

$278.62

$288.48

50 Day Range

MA: $318.08

$278.76

$337.38

2 Week Range

Now: $287.87

$260.52

$346.85

Volume

4,759,193 shs

Average Volume

2,470,613 shs

Market Capitalization

$154.74 billion

P/E Ratio

36.86

Dividend Yield

3.17%

Beta

0.6

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad